BMB-105
Pharmaceutical compound
From Wikipedia, the free encyclopedia
BMB-105 is a selective serotonin 5-HT2C receptor agonist of the phenylcyclopropylmethylamine (PCPMA) family which is under development for the treatment of excessive appetite and other symptoms in Prader–Willi syndrome.[1][2][3][4] It is taken orally.[1]
- None
| Clinical data | |
|---|---|
| Other names | BMB105 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2C receptor agonist |
| ATC code |
|
The drug is described as a highly selective biased agonist of the serotonin 5-HT2C receptor, with activation of the Gq signaling pathway but minimal β-arrestin recruitment.[4]
BMB-105 is under development by Bright Minds Biosciences.[1][2][3][4] As of November 2025, it is in phase 1 clinical trials.[1][3] The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication.[3][4]
The exact chemical structure of BMB-105 does not yet appear to have been disclosed.[1] However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine.[4]